These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22372351)

  • 1. Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500.
    Zur B; Holdenrieder S; Walgenbach-Brünagel G; Albers E; Stoffel-Wagner B
    Clin Lab; 2012; 58(1-2):97-105. PubMed ID: 22372351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new LOCI technique of Dimension Vista 1500 and Immulite 2000 XPI.
    Zur B; Holdenrieder S; Albers E; Walgenbach-Brünagel G; Stoffel-Wagner B
    J Immunoassay Immunochem; 2012; 33(4):435-45. PubMed ID: 22963492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elecsys CEA, PSA and AFP. Clinical results of a multicentre evaluation.
    Uhl W; Chan DW; Jones K; Kelley C; Assmann G; von Eckardstein A; Sägers A; Yvert JP; Schneider AM; Torralba A; Fuentes-Arderiu X; Gonzalez de la Presa B; Vives M; Greiling H; Eberle A; Niederau CM; Cremer P; Reiter W; Vogeser M; Neumeier D; Luppa P; Huber U
    Wien Klin Wochenschr; 1998; 110 Suppl 3():51-61. PubMed ID: 9677672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cardiopulmonary resuscitation on levels of tumour markers.
    Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
    Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
    Slev PR; La'ulu SL; Roberts WL
    Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A preliminary study of PSA level in 646 healthy men in Beijing].
    Shao Q; Guo Y; Guo H
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):591-2. PubMed ID: 11798824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive detection of carcinoembryonic antigen with magnetic nano-bead and upconversion nanoparticles-based immunoassay.
    Huang Z; Wu S; Duan N; Hua D; Hu Y; Wang Z
    J Pharm Biomed Anal; 2012 Jul; 66():225-31. PubMed ID: 22464562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
    Battikhi MN
    Prostate Cancer Prostatic Dis; 2003; 6(3):256-60. PubMed ID: 12970732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of alpha-fetoprotein and carcinoembryonic antigen in human serum by time-resolved fluoroimmunoassay.
    Matsumoto K; Yuan J; Wang G; Kimura H
    Anal Biochem; 1999 Dec; 276(1):81-7. PubMed ID: 10585747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.
    Kort SA; Martens F; Vanpoucke H; van Duijnhoven HL; Blankenstein MA
    Clin Chem; 2006 Aug; 52(8):1568-74. PubMed ID: 16762996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of MARK BTM for Quantitative Measurement of Three Tumor Markers: Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen.
    Hwang H; Kim J; Choi J; Kim KH; Han HS
    Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
    Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
    J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.